(Reuters) – Seagen said on Wednesday that its breast cancer therapy combined with Roche’s Kadcyla helped extend the time patients lived without their disease progressing in a late-stage study.
Pfizer Inc has agreed to acquire Seagen in a $43 billion deal to gain access to its targeted cancer therapies.
The therapy, Tukysa, known chemically as tucatinib, is approved in the United States for use in combination with Roche’s Herceptin and Xeloda in patients whose cancer has progressed or metastasized despite at least one prior round of treatment.
Kadcyla belongs to a class of drugs called antibody-drug conjugates (ADCs), which have been described as “guided missiles” cancer drugs.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)